• Abivax posted a first-half operating loss of EUR 140.3 million, widening 49.73% year over year.
• Net loss widened 64.58% to EUR 165.9 million, while operating income edged up 19.05% to EUR 2.5 million.
• R&D costs climbed 38.38% to EUR 107.9 million, and G&A expenses rose 86.5% to EUR 30.4 million.
• Sales and marketing spend more than doubled to EUR 4.6 million, and cash, cash equivalents and short-term investments totaled EUR 402.4 million at June 30.
• Chris Rabbat will succeed Fabio Cataldi as chief medical officer in Q4 2026, while Tim Kelly was appointed chief technical officer effective immediately.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2402636_en) on September 21, 2026, and is solely responsible for the information contained therein.